Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
08 mai 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused...
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
02 mai 2023 07h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
27 mars 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
06 mars 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa- Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib ...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
23 févr. 2023 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
09 févr. 2023 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Provides 2023 Outlook
06 janv. 2023 07h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
29 nov. 2022 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates...
Aclaris Therapeutics Announces Key Leadership Transitions
22 nov. 2022 16h01 HE
|
Aclaris Therapeutics, Inc.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr....
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
10 nov. 2022 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...